MarketingRx roundup: Aduhelm can’t get traction with docs; Pfizer presses vaccine effort during NFL playoffs
While much of the pharma industry’s attention pivoted to CMS’ preliminary decision last week to only cover Biogen’s controversial Alzheimer’s drug Aduhelm in clinical …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
